Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 20/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14092357 | 1.00 | GHSR (0.77) | GHSRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL20079231 | 0.97 | GHSR (0.72) | GHSRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL804854 | 0.97 | GHSR (0.72) | GHSRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14092366 | 0.94 | GHSR (0.69) | GHSRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14092408 | 0.90 | GHSR (0.63) | GHSRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL18517342 | 0.89 | GHSR (0.62) | GHSRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL804938 | 0.89 | GHSR (0.87) | GHSRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14116359 | 0.88 | GHSR (0.63) | GHSRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14046958 | 0.88 | GHSR (0.64) | GHSRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14092355 | 0.88 | GHSR (0.64) | GHSRCYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071412-A1 | METHODS OF USING MACROCYCLIC AGONISTS OF THE GHRELIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL MOTILITY DISORDERS | FRASER GRAEME L (BE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071412-A1 | METHODS OF USING MACROCYCLIC AGONISTS OF THE GHRELIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL MOTILITY DISORDERS | FRASER GRAEME L (BE) | 2012-03-22 | — | — | US | disclosed |
| US-8088733-B2 | Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders | TRANZYME PHARMA INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-8088733-B2 | Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders | TRANZYME PHARMA INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20080194672-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | TRANZYME PHARMA INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194672-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | TRANZYME PHARMA INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080051383-A1 | METHODS OF USING MACROCYCLIC AGONISTS OF THE GHRELIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL MOTILITY DISORDERS | TRANZYME PHARMA INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051383-A1 | METHODS OF USING MACROCYCLIC AGONISTS OF THE GHRELIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL MOTILITY DISORDERS | GHSR, GIPR, GHRHR | GHSR 1/4885CYP3A4 1192/4885CYP2D6 719/4885 |
| US-20120071412-A1 | METHODS OF USING MACROCYCLIC AGONISTS OF THE GHRELIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL MOTILITY DISORDERS | GHSR, GIPR, GHRHR | GHSR 1/4885CYP3A4 1192/4885CYP2D6 719/4885 |
| US-20080194672-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | GHSR, GHRHR, GIPR | GHSR 1/4885CYP3A4 2898/4885CYP2D6 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.